$0.53
3.4%
Downside
Day's Volatility :6.57%
Upside
3.28%
1.92%
Downside
52 Weeks Volatility :88.82%
Upside
88.6%
Period | Silexion Therapeutics Corp | Index (Russel 2000) |
---|---|---|
3 Months | -73.07% | 0.0% |
6 Months | -73.07% | 0.0% |
1 Year | -73.07% | 0.0% |
3 Years | -73.07% | -21.1% |
Market Capitalization | 9.9M |
Book Value | $4.67 |
Earnings Per Share (EPS) | -0.66 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -62.13% |
Return On Equity TTM | -116.66% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -1.4M |
Diluted Eps TTM | -0.66 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Sell
Neutral
Buy
Silexion Therapeutics Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Silexion Therapeutics Corp | -52.25% | -73.07% | -73.07% | -73.07% | -73.07% |
Regeneron Pharmaceuticals, Inc. | -10.06% | 10.55% | 30.05% | 89.27% | 274.48% |
Novo Nordisk A/s | -12.62% | -6.24% | 35.65% | 145.66% | 372.59% |
Alnylam Pharmaceuticals, Inc. | 8.37% | 82.34% | 59.06% | 41.03% | 258.58% |
Vertex Pharmaceuticals Incorporated | -2.23% | 13.76% | 34.75% | 162.16% | 172.77% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Silexion Therapeutics Corp | NA | NA | NA | 0.0 | -1.17 | -0.62 | NA | 4.67 |
Regeneron Pharmaceuticals, Inc. | 27.85 | 27.85 | 1.43 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.39 | 40.39 | 1.82 | 3.45 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Silexion Therapeutics Corp | NA | $9.9M | -73.07% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $115.9B | 274.48% | 27.85 | 32.04% |
Novo Nordisk A/s | Buy | $531.4B | 372.59% | 40.39 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.3B | 258.58% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.0B | 172.77% | 32.84 | -4.74% |
Organization | Silexion Therapeutics Corp |
Employees | 0 |
CEO | Mr. Ilan Hadar M.B.A. |
Industry | Miscellaneous |
Spdr S&p Global Dividend Etf
$0.53
-1.46%
Flotek Industries Inc
$0.53
-1.46%
Trio Petroleum Corp
$0.53
-1.46%
Ft Cboe Vest Us Eqy D Bu-may
$0.53
-1.46%
Cherry Hill Mortgage Investment Corp
$0.53
-1.46%
Invesco Bulletshares 2025 Hi
$0.53
-1.46%
Invesco Large Cap Value Etf
$0.53
-1.46%
Ft Cboe Vest Us Equity Moderate Buffer Etf - Apr
$0.53
-1.46%
Graniteshares 2x Long Msft Daily Etf
$0.53
-1.46%